Editas Medicine (EDIT) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Editas Medicine published the results on November 9, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Editas Medicine has no product sales. Its revenue line, collaboration and other research and development revenues, depends on partner milestones and license payments, so it moves sharply from quarter to quarter.
• Per-share figures reflect the May 2026 public offering of 55,555,556 shares with accompanying warrants, which lifted the weighted share count.

Source: Editas Medicine Q3 2026 results, November 9, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and net loss per share, each as first reported. Q4 2025 figures are from the Q4 2025 release, which gave revenue of $24.7 million and a $0.06 loss per share.

We do not hold a confirmed date for Editas Medicine's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 9, 2026

Editas Medicine reports a single revenue line, collaboration and other research and development revenues. It was $10.4 million in Q3 2026, up $2.8 million or 37% from $7.5 million, which Editas put down mainly to revenue from clinical development milestones achieved by a strategic partner. (Editas Medicine Q3 2026 release, Nov 9, 2026; Editas Medicine Form 10-Q, Q3 2026, Nov 9, 2026)

That partner work includes the Bristol Myers Squibb collaboration. In the quarter a second IND/CTA was accepted for BMS-986527, a CD70 healthy-donor allogeneic CAR-T therapy engineered with Editas's Cas12a gene editing technology, which triggered a milestone payment to Editas. (Editas Medicine Q3 2026 release, Nov 9, 2026)

Editas's other income sources are its license agreement with Vertex and a purchase and sale agreement with DRI Healthcare Acquisitions LP, under which it sold future revenues. It carries a liability for sale of future revenues of $7.5 million current and $49.3 million non-current, and records interest expense on it: $1.1 million in Q3 2026, against $2.4 million. (Editas Medicine Form 10-Q, Q3 2026, Nov 9, 2026)

Deferred revenue was $32.3 million current and $4.0 million non-current at September 30, 2026, against $44.5 million, all non-current, at December 31, 2025. Over nine months revenue was $25.1 million, against $15.8 million a year earlier. (Editas Medicine Q3 2026 release, Nov 9, 2026)

Editas Medicine reports GAAP results only. Its net loss was $23.4 million, or $0.15 per share, against $25.1 million, or $0.28 per share. Research and development expense rose $1.4 million to $21.2 million on higher sublicense and license fees and EDIT-401 work, and general and administrative expense rose $1.2 million to $13.5 million on intellectual property and patent fees. (Editas Medicine Q3 2026 release, Nov 9, 2026)

Most of the drop in the per-share loss comes from the share count. Weighted-average shares were 153,604,267, against 90,090,397 a year earlier, after the May 2026 offering of 55,555,556 shares and accompanying warrants, which raised $116.9 million net. Stock-based compensation was $2.6 million in the quarter. (Editas Medicine Q3 2026 release, Nov 9, 2026; Editas Medicine Form 10-Q, Q3 2026, Nov 9, 2026)

The nine-month comparison carries a one-off: restructuring and impairment charges of $66.9 million in the first nine months of 2025, against a $1.3 million credit in 2026. (Editas Medicine Q3 2026 release, Nov 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Editas Medicine gives no revenue or EPS guidance. Its release says cash, cash equivalents and marketable securities of $190.2 million at September 30, 2026 should fund operating expenses and capital expenditures into the second half of 2028. (Editas Medicine Q3 2026 release, Nov 9, 2026)

For EDIT-401, an in vivo LDLR gene editing medicine for hyperlipidemia, Editas expects to begin patient dosing in the Phase 1/2 Strive study in Australia this year, report initial safety and tolerability data in the first quarter of 2027, and have topline Part 1 results in the second half of 2027. (Editas Medicine Q3 2026 release, Nov 9, 2026)

A consensus figure is the average of the models published by the analysts who cover Editas Medicine, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Editas Medicine's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning EDIT is on is EDIT a buy or a sell?, what analysts expect next is on the EDIT forecast, and what the company does is on the Editas Medicine (EDIT) stock page.

Every number on this page can be traced to a document Editas Medicine published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.